Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Direct Meds vs Wisp

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

5.4

Direct Meds

Best for listed for transparent disclosure — see FDA warning and BBB complaint pattern before considering
★★☆☆2.7

Starting at $249/mo

CompoundedSemaglutideTirzepatideSublingual Option
Visit Direct Meds
7.0

Wisp

Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested
★★★3.5

Starting at $225/mo

Brand WegovyBrand ZepboundBrand SaxendaCompounded Sublingual Semaglutide
Visit Wisp

Side-by-Side Comparison

FeatureDirect MedsWisp
Overall Score5.4/107.0/10
Starting Price$249/mo$225/mo
Editorial Rating2.7 ★ /53.5 ★ /5
Features5 features6 features
States Available00
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA Warnings1 warningNone

Pros & Cons

Direct Meds

Pros

  • Both semaglutide and tirzepatide available in injection and sublingual formats
  • All-inclusive pricing with medication, consultations, supplies, and 1–2 day temperature-controlled shipping
  • LegitScript certification confirmed (verified December 2025)
  • Named 503A pharmacy partners: CraftedRx (Warrenton, MO) and ChemistryRx (Folcroft, PA)

Cons

  • FDA warning letter September 9, 2025 for misleading marketing of compounded GLP-1s as equivalent to FDA-approved drugs — compliance status post-warning not publicly documented
  • Extensive Better Business Bureau complaint pattern (rating 1.12/5 across 226 reviews as of April 2026) documenting a hidden 3-month commitment trap: multiple users report being charged $940+ for a 3-month supply when they believed they were purchasing 1 month. Direct Meds disputes the characterization but the complaint volume is material
  • Katalys program name 'Direct Meds GLP-1 Offers Top Funnels' and $280 CPA payout indicate aggressive performance-marketing optimization, which can correlate with conversion-first UX patterns
  • Rating discrepancy: Trustpilot 4.6/5 from 7,500+ reviews vs. BBB 1.12/5 from 226 reviews — suggests either review-solicitation bias or genuine unresolved customer experience issues
  • Not available in Mississippi, Louisiana, or California
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Incorporated May 2024 — less than 2 years of operational history
  • Auto-renewal continues until manual email cancellation; BBB complaints report retention-department friction and hold times exceeding 15 minutes

Wisp

Pros

  • Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
  • LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
  • Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing

Cons

  • EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
  • Pharmacy partners not publicly named
  • States served list not publicly enumerated

Our Verdict

Winner: WispScore: 7.0/10

Wisp edges out Direct Meds with a higher overall score of 7.0/10 and is particularly strong for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested. Direct Meds remains a solid alternative, especially if you're looking for listed for transparent disclosure — see FDA warning and BBB complaint pattern before considering.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.